Amgen Wins FDA OK For Cancer Drug

11/18/10

Amgen (NASDAQ: AMGN), the world’s largest biotech company, said today it has won clearance from the FDA to start marketing denosumab (Xgeva) to reduce fractures in cancer patients with solid tumors that have spread to the bones. This is the second major approved use of the drug, which was first cleared in June as a treatment for osteoporosis. Xconomy described Amgen’s strategy for fighting cancer in the bones, and the role of Seattle-based scientist Bill Dougall, back in this story from October 2008.

By posting a comment, you agree to our terms and conditions.